William Bryan Ewing

US Patent:

57313156, Mar 24, 1998

Filed:

Dec 6, 1996

Appl. No.:

8/761414

Inventors:

William R. Ewing - Downingtown PA
Michael R. Becker - Norristown PA
Yong Mi Choi-Sledeski - Collegeville PA
Heinz W. Pauls - Collegeville PA
Daniel G. McGarry - King of Prussia PA
Roderick S. Davis - West Chester PA
Alfred P. Spada - Lansdale PA

Assignee:

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA

International Classification:

C07D40102
A61K 3140
A61K 31435

US Classification:

514269

Abstract:

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

US Patent:

60340932, Mar 7, 2000

Filed:

Aug 6, 1998

Appl. No.:

9/130336

Inventors:

William R. Ewing - Downingtown PA
Michael R. Becker - Norristown PA
Yong Mi Choi-Sledeski - Collegeville PA
Heinz W. Pauls - Collegeville PA
Daniel G. McGarry - King of Prussia PA
Roderick S. Davis - West Chester PA
Alfred P. Spada - Lansdale PA

Assignee:

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA

International Classification:

C07D40102
A61K 3140
A61K 31435

US Classification:

514301

Abstract:

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

US Patent:

59589183, Sep 28, 1999

Filed:

Nov 21, 1997

Appl. No.:

8/976034

Inventors:

William R. Ewing - Downingtown PA
Michael R. Becker - Norristown PA
Henry W. Pauls - Collegeville PA
Daniel L. Cheney - Collegeville PA
Jonathan Stephen Mason - Phoenixville PA
Alfred P. Spada - Lansdale PA
Yong Mi Choi-Sledeski - Collegeville PA

Assignee:

Rhone-Poulenc Rorer Pharmaceuticals Inc.

International Classification:

C07D40102
A61K 3140
A61K 31435

US Classification:

514212

Abstract:

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

US Patent:

20140163002, Jun 12, 2014

Filed:

Aug 6, 2012

Appl. No.:

14/236968

Inventors:

Patrick Y.S. Lam - Chadds Ford PA, US
Charles G. Clark - Cherry Hill NJ, US
James R. Corte - Lawrenceville NJ, US
William R. Ewing - Yardley PA, US
Paul J. Gilligan - Wilmington DE, US
Yoon Jeon - Belle Mead NJ, US
Wu Yang - Princeton Junction NJ, US
Yufeng Wang - North Brunswick NJ, US

Assignee:

BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

International Classification:

C07D 498/06
C07D 471/06
C07D 487/06

US Classification:

51421018, 540460, 5142288, 540472, 514322, 540461, 514274, 51425303, 540456

Abstract:

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.